Tumor Cell Or Cancer Cell Patents (Class 435/7.23)
  • Patent number: 10344315
    Abstract: A method of retrieving fetal cells from an endocervical sample by removing the mucus from the endocervical sample by disassociating fetal cells and maternal cells in the endocervical sample; and isolating disassociated fetal cells from other cells in the endocervical sample. Also provided is a method of retrieving fetal cells from an endocervical sample, by obtaining a mixture of disassociated cells prepared by the above method, treating the cells with a fetal-specific antibody, identifying cells that have bound to the fetal-specific antibody, and isolating the identified cells. The disassociated cell prepared by the above method can be analyzed and used for a variety of purposes including, but not limited to, the identification of fetal cells among cervical cells, determination of fetal cell density to predict high risk pregnancy, genetic analysis of fetal cells, and determination of growth factor or other biomarker expression to predict obstetrical disorders.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: July 9, 2019
    Assignee: Wayne State University
    Inventors: D. Randall Armant, Michael P. Diamond
  • Patent number: 10316092
    Abstract: The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the B7-H5 ligand of the B7-H5:CD28H pathway, and to the uses of such molecules in the treatment and diagnosis of autoimmune disease, transplant rejection and other inflammatory diseases.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: June 11, 2019
    Assignees: THE JOHN HOPKINS UNIVERSITY, MEDIMMUNE, LLC
    Inventors: Sheng Yao, Lieping Chen, Linda Liu, Solomon Langermann
  • Patent number: 10311571
    Abstract: The present invention relates to an image analysis method for providing information for supporting illness development prediction regarding a neoplasm in a human or animal body. The method includes receiving for the neoplasm first and second image data at a first and second moment in time, and deriving for a plurality of image features a first and a second image feature parameter value from the first and second image data. These feature parameter values being a quantitative representation of a respective image feature. Further, calculating an image feature difference value by calculating a difference between the first and second image feature parameter value, and based on a prediction model deriving a predictive value associated with the neoplasm for supporting treatment thereof. The prediction model includes a plurality of multiplier values associated with image features.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: June 4, 2019
    Assignee: Stichting Maastricht Radiation Oncology “Maastro-Clinic”
    Inventors: Philippe Lambin, Sara Joao Botelho de Carvalho, Ralph Theodoor Hubertina Leijenaar
  • Patent number: 10279018
    Abstract: Provided herein are immunogenic compositions (vaccines) and methods for immunizing a subject with the immunogenic compositions for inducing an adaptive immune response directed specifically against senescent cells for treatment and prophylaxis of age-related diseases and disorders, and other diseases and disorders associated with or exacerbated by the presence of senescent cells. The immunogenic compositions provided herein comprise at least one or more senescent cell-associated antigens, polynucleotides encoding senescent cell-associated antigens, and recombinant expression vectors comprising the polynucleotides for use in administering to a subject in need thereof.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: May 7, 2019
    Assignees: UNITY BIOTECHNOLOGY, INC., BUCK INSTITUTE FOR RESEARCH ON AGING, KYTHERA BIOPHARMACEUTICALS, INC.
    Inventors: Alain Philippe Vasserot, Serge Lichtsteiner, Judith Campisi
  • Patent number: 10274501
    Abstract: Assays for detecting antibodies to pharmaceutical preparations, food allergens and environmental allergens are described.
    Type: Grant
    Filed: April 30, 2016
    Date of Patent: April 30, 2019
    Assignee: ANP Technologies, Inc.
    Inventors: Ray Yin, Jing Pan, Yli Remo Vallejo, Thomas Small, Dujie Qin, De Chen
  • Patent number: 10261099
    Abstract: Chemokine receptor CCR4 and its ligands CCL17 and CCL22 are used as markers for the identification and/or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumour progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients according to their suitability for treatment with anti-cancer agents. Information of diagnostic character is provided by measuring the level of one or more of CCR4, CCL17 and CCL22 present in a patient sample. Methods of treatment of cancer patients which agents that modulate the activity of CCR4, CCL17 and CCL22. Methods of screening for agents which modulate the biological activities of CCR4, CCL17 and CCL22 provide anti-cancer agents.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: April 16, 2019
    Assignee: Cancer Research Technology Ltd.
    Inventors: Frances Balkwill, Violet Slettenaar, Julia Wilson, Yaohe Wang, Tiziana Schioppa
  • Patent number: 10255410
    Abstract: Disclosed herein are methods for treating Barrett's metaplasia and esophageal adenocarcinoma and methods for determining mutational load as a predictor of the risk of disease progression from Barrett's metaplasia to esophageal adenocarcinoma.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: April 9, 2019
    Assignee: INTERPACE DIAGNOSTICS CORPORATION
    Inventors: Eric Matthew Gayle Ellsworth, Sydney David Finkelstein, Sara Ann Jackson, Brendan Corcoran, Dennis Morgan Smith, Jr.
  • Patent number: 10234447
    Abstract: The present invention relates to a method for the diagnosis of tumoural conditions and/or of the corresponding state of advance, wherein a specimen of an organic fluid taken from the patient and having a high probability of containing at least one circulating tumor cell (CTC) or a disseminated tumor cell (CTD) is enriched in a population of CTCs or CTDs. According to the invention, at least one type of CTCs or CTDs is isolated by selecting individually single cells in a microfluidic device so to constitute a diagnostic specimen having a purity of at least 90%. On the specimen thus obtained there is subsequently performed a molecular analysis such as to highlight a characteristic thereof suited to enabling diagnosis.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: March 19, 2019
    Assignee: Menarini Silicon Biosystems S.p.A.
    Inventors: Nicolò Manaresi, Gianni Medoro, Giuseppe Giorgini
  • Patent number: 10233484
    Abstract: Disclosed herein are methods and systems for detection of a microorganism of interest using an amplification assay. The methods and systems utilize the specificity of binding agents, such as antibodies, to rapidly detect low levels of a specific microorganism present in a sample. In certain embodiments, antibodies are bound to a large number of the available binding sites on a microorganism.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: March 19, 2019
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Dwight Lyman Anderson, Ben Barrett Hopkins, Jose S. Gil, Stephen Erickson, Ekaterina Kovacheva
  • Patent number: 10227656
    Abstract: Embodiments of the present disclosure concern methods and compositions for prognosis, diagnosis, and/or treatment of prostate cancer or breast cancer, for example. Certain embodiments of the disclosure concern assaying for the expression level of TDRD1. Particular embodiments concern treating an individual with a particular cancer therapy when the expression level of TDRD1 is overexpressed.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: March 12, 2019
    Assignee: Baylor College of Medicine
    Inventors: Bin He, Rainer B. Lanz, Nicholas Mitsiades, Qin Feng
  • Patent number: 10201598
    Abstract: Compositions comprising a nucleic acid molecule that encodes TB esat-6 proteins are disclosed. Methods of inducing an immune response against TB an individual are disclosed. Method of treating an individual who has been diagnosed with TB are disclosed. Method of preventing TB infection in an individual are disclosed.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: February 12, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Daniel Villarreal
  • Patent number: 10188691
    Abstract: The present disclosure provides methods to treat conditions, including cancer, using compounds that can target resistant cancer cells. The compounds can be used to sensitize resistant cancer cells or decrease the proliferation of cells. The compounds can target proteins in the DNA damage repair pathway leading to a decrease in DNA damage repair in target cells.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: January 29, 2019
    Assignee: SyntheX, Inc.
    Inventors: Charly Chahwan, Maria Soloveychik
  • Patent number: 10175241
    Abstract: The present invention relates to the assessment of lung cancer. It discloses the use of protein ASC in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample, derived from an individual by measuring ASC in the sample. Measurement of ASC can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: January 8, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Herbert Andres, Marie-Luise Hagmann, Johann Karl, Markus Roessler, Michael Tacke
  • Patent number: 10168332
    Abstract: The present invention relates to a method for predicting the prognosis of acute myeloid leukemia relapse. According to the present invention, the prognosis of acute myeloid leukemia relapse can be predicted by analyzing changes in a bone marrow microenvironment during the early diagnosis of leukemia.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: January 1, 2019
    Assignee: The Catholic University of Korea Industry-Academic Cooperation Foundation
    Inventor: Il Hoan Oh
  • Patent number: 10145850
    Abstract: This invention relates to a method of detecting or determining the presence of prostate cancer cells in a sample of body fluid from a subject comprising: (i) isolating cells from said sample to provide a cell sample; (ii) contacting said cell sample with a specific binding member capable of binding a prostate antigen; and/or (iii) contacting said cell sample with a specific binding member capable of binding a minichromosome maintenance (MCM) polypeptide(s); and (iv) determining the binding of said specific binding member(s) to the cell sample.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: December 4, 2018
    Inventor: David Brian Galloway
  • Patent number: 10111954
    Abstract: The present invention concerns combinations of two or more agents for inducing an immune response to cancer or infectious disease. Agents may include leukocyte redirecting complexes, antibody-drug conjugates, interferons (preferably interferon-?), and/or checkpoint inhibitor antibodies. The leukocyte redirecting complexes have at least one binding site for a leukocyte antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3× anti-CD19 bispecific antibody, although antibodies against other leukocyte antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of cells associated with cancer or infectious disease.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: October 30, 2018
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi, Diane Rossi, Hans J. Hansen
  • Patent number: 10107814
    Abstract: The invention provides a method of detecting a subject suffering from, or at risk of suffering from, bladder cancer the method comprising i) providing a body fluid sample isolated from a subject; ii) isolating cells from said sample to provide a cell sample; iii) contacting the sample with a specific binding member capable of binding to a minichromosome maintenance (MCM) polypeptide(s); iv) determining the binding of said specific binding member to the cell sample; v) counting those cells in said cell sample which bound to said specific binding member to provide a cell count; vi) determining, based on the cell count, whether the subject has, or is at risk of having, bladder cancer.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: October 23, 2018
    Inventors: David Galloway, Nick Coleman
  • Patent number: 10098971
    Abstract: The present disclosure relates to polymers which contain a hydrophobic and hydrophilic segment which is sensitive to pH. In some aspects, the polymers form a micelle which is sensitive to pH and results in a change in fluorescence based upon the particular pH. In some aspects, the disclosure also provides methods of using the polymers for the imaging of cellular or extracellular environment or delivering a drug.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: October 16, 2018
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Jinming Gao, Gang Huang, Tian Zhao, Xinpeng Ma, Yiguang Wang, Yang Li, Baran D. Sumer
  • Patent number: 10093705
    Abstract: The invention provides compositions and methods for brown fat induction and activity through modulation of Fndc5 activity and/or expression. Also provided are methods for preventing or treating metabolic disorders in a subject through modulation of Fndc5 activity and/or expression. Further provided are methods for identifying compounds that are capable of modulating Fndc5 activity and/or expression.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: October 9, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Pontus Bostrom
  • Patent number: 10087485
    Abstract: Compositions and methods are provided for DNA barcoding of designer mononucleosome and polynucleosome (chromatin array) libraries for use, for example, for the profiling of chromatin readers, writers, erasers, and modulators thereof.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: October 2, 2018
    Assignee: The Trustees of Princeton University
    Inventors: Tom W. Muir, Uyen T. T. Nguyen, Manuel M. Mueller
  • Patent number: 10085987
    Abstract: This invention provides a method of identifying one or more subgroups of cancer patients that are likely to benefit from treatment with a monocarboxylate transporter (MCT) protein inhibitor comprising: (a) obtaining a sample of a cancer/tumor tissue from each of said cancer patients; (b) determining the expression level of stromal MCT4 protein in each of said samples of cancer/tumor tissue to obtain a first dataset; and (c) using the expression level of the stromal MCT4 protein from said first dataset to classify each of said sets of one or more cancer patients as stromal MCT4-positive or stromal MCT4-negative, wherein the cancer patients classified as stromal MCT4-positive are patients that are more likely to benefit from treatment with said MCT protein inhibitor. This invention also provides related methods for treating a cancer/tumor whose stromal component expresses the MCT4 protein in a patient.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: October 2, 2018
    Assignee: THOMAS JEFFERSON UNIVERSITY
    Inventors: Michael P. Lisanti, Federica Sotgia
  • Patent number: 10067124
    Abstract: To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample. By using a blood sample in a condition in which a blood coagulation factor is not activated is used as a sample, the degradation of ProGRP is suppressed, whereby it is possible to store a sample for a long period of time and to improve the accuracy of an assay.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: September 4, 2018
    Assignees: Abbott Laboratories, Abbott Japan Co. Ltd.
    Inventors: Toru Yoshimura, Kenju Fujita, Barry L. Dowell
  • Patent number: 10055840
    Abstract: A method for identifying biomarker-positive tumor cells is disclosed. The method includes, for example, reading a first digital image and a second digital image into memory, the first and second digital image depicting the same area of a first slide; identifying a plurality of nuclei and positional information of said nuclei by analyzing the light intensities in the first digital image; identifying cell membranes which comprise the biomarker by analyzing the light intensities in the second digital image and by analyzing the positional information of the identified nuclei; and identifying biomarker-positive tumor cells in said area, wherein a biomarker-positive tumor cell is a combination of one identified nucleus and one identified cell membrane that surrounds the identified nucleus.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: August 21, 2018
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Srinivas Chukka, Quan Yuan
  • Patent number: 10053511
    Abstract: Provided herein are anti-CLDN antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: August 21, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Marianne Santaguida, Monette Aujay, Laura Saunders, David Liu, Orit Foord, Robert A. Stull, Paul Anthony Escarpe
  • Patent number: 10048213
    Abstract: A method of forming of an item includes: selecting a component of the item that is formed of an element; mixing one or more identifiable additives with the element; forming the component with the mixture; performing an atomic level test on at least a portion of the component; and recording the results of the test.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: August 14, 2018
    Assignee: RAYTHEON COMPANY
    Inventors: Andrew M. Wilds, Philip C. Theriault, Michael K. Burkland
  • Patent number: 10041948
    Abstract: This document relates to materials and methods involved in assessing inflammatory bowel disease patients at risk for developing cancer. For example, materials and methods for monitoring colorectal cancer risk in ulcerative colitis patients are provided.
    Type: Grant
    Filed: October 12, 2011
    Date of Patent: August 7, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Megan Garrity-Park, Thomas C. Smyrk, Edward V. Loftus, Jr., William J. Sandborn
  • Patent number: 10032064
    Abstract: The disclosure features methods and systems that include a detector configured to obtain multiple images of a sample stained with first and second stains, where the first and second stains have similar spectral absorption and emission profiles, and an electronic processor configured to decompose the multiple images into an unmixed image set, where the unmixed image set includes a first unmixed image corresponding to the first stain and a second unmixed image corresponding to the second stain, and identify nuclear regions in the sample based on the first unmixed image and identify cytoplasm regions in the sample based on the second unmixed image.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: July 24, 2018
    Assignee: Cambridge Research & Instrumentation, Inc.
    Inventor: Clifford C. Hoyt
  • Patent number: 10016518
    Abstract: An imaging agent comprising a conjugate of an oligosaccharide moiety with an imaging moiety. The oligosaccharide is Lewis A or Lewis B or a mimetic thereof, or a pharmaceutically acceptable salt or PEGylated form of Lewis A or Lewis B or its mimetics. Lewis A and Lewis B and its mimetics are also provided for use in the therapeutic treatment of inflammatory diseases, autoimmune diseases and cancer.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: July 10, 2018
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Daniel Anthony, Benjamin Guy Davis, Guillaume Bort
  • Patent number: 10017724
    Abstract: A microfluidic device for more accurately modeling the in vitro environment in which cancer occurs is disclosed. The device comprises a surface defining one or more microfluidic channels that may further comprise one or more endothelial cells, a first three dimensional scaffold comprising one or more cancer cells that is spatially separated from the one or more microfluidic channels, and a second three dimensional scaffold comprising one or more stromal cells, at least a portion of which is interposed between the one or more microfluidic channels and the first three dimensional scaffold. The second three dimensional scaffold is in fluid communication with both the first three dimensional scaffold and the one or more microfluidic channels. The device can be used to assay anti-cancer agents, or as a system for modeling the growth, behavior, or metastasis and tumor formation of cancer cells.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: July 10, 2018
    Assignees: Arizona Board of Regents on Behalf of Arizona State University, Massachusetts Institute of Technology
    Inventors: Mehdi Nikkhah, Roger D. Kamm, Danh Truong
  • Patent number: 9989524
    Abstract: The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: June 5, 2018
    Assignee: SANOFI
    Inventors: Jochen Kruip, Susanta K. Sarkar, Mathias Gebauer, Christian Lange, Ingo Focken
  • Patent number: 9989531
    Abstract: Methods of stratifying a subject having or at risk for developing adolescent idiopathic scoliosis (AIS) into diagnostically or clinically useful subclasses are provided. The stratification is based on the subject's PTP? expression and/or activity and/or PIPK1? expression and/or activity. Also provided are methods of predicting the risk of developing a scoliosis also based on the subject's PTP? expression and/or activity and/or PIPK1? expression and/or activity; and methods of increasing GiPCR signaling in cells of a subject in need thereof comprising administering to the subject's cells an effective amount of an inhibitor of PIPK1? tyrosine phosphorylation; an activator of PIPK1Y tyrosine dephosphorylation; and/or an inhibitor of PIPK1? expression and/or activity.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: June 5, 2018
    Assignee: Chu Sainte-Justine
    Inventors: Alain Moreau, Marie-Yvonne Akoume Ndong, Mohamed Elbakry
  • Patent number: 9983209
    Abstract: The present invention relates to the BAD pathway's influence on development, progression, chemo-sensitivity, and overall survival for multiple human cancers and its potential as a therapeutic target to increase chemo-sensitivity. BAD pathway expression was associated with the development and/or progression of breast, colon, and endometrial cancers, relapse-free survival from breast cancer, and overall survival from ovarian, colon, and brain cancers. Expression was also associated with in vitro sensitivity to a range of cytotoxic agents. pBAD levels were higher in cancer versus immortalized normal cells and chemo-resistant versus—sensitive cancer cells and associated with increased cell proliferation.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: May 29, 2018
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Johnathan M. Lancaster, Douglas C. Marchion, Yin Xiong
  • Patent number: 9982306
    Abstract: We determined the sequence of ATRX and DAXX in 447 cancers from various sites. We found mutations most commonly in pediatric glioblastoma multiformae (GBM) (11.1%), adult GBM (6.5%), oligodendrogliomas (7.7%) and medulloblastomas (1.5%); and showed that Alternative Lengthening of Telomeres (ALT), a telomerase-independent telomere maintenance mechanism found in cancers that have not activated telomerase, perfectly correlated with somatic mutations of either gene. In contrast, neuroblastomas, and adenocarcinomas of the ovary, breast, and pancreas were negative for mutations in ATRX and DAXX. Alterations in ATRX or DAXX define a specific molecular pathway that is closely associated with an alternative telomere maintenance function in human cancers.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: May 29, 2018
    Assignees: Duke University, The Johns Hopkins University
    Inventors: Hai Yan, Darell Bigner, Bert Vogelstein, Kenneth W. Kinzler, Alan Meeker, Ralph Hruban, Nickolas Papadopoulos, Luis Diaz, Yuchen Jiao
  • Patent number: 9937193
    Abstract: The present invention relates to a method for treating a cancer with the combination of a topoisomerase II inhibitor (TOP2 inhibitor) and a histone deacetylation inhibitor (HDACi), provides synergistic cancer cell-killing effects, and prolonged overall survival, especially when the expression of checkpoint kinase 1 (CHK-1) is low.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: April 10, 2018
    Assignee: NATIONAL YANG-MING UNIVERSITY
    Inventor: Jin-Hwang Liu
  • Patent number: 9932639
    Abstract: The present invention is related to a method for analyzing a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining, on a non protein basis, the expression level of three genes of interest, said genes being correlated with the Estrogen receptor (ESR) status in the sample, c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient from the outcome of the comparison in step (c); and treating based on said outcome.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: April 3, 2018
    Inventors: Ralph Markus Wirtz, Ralf Kronenwett
  • Patent number: 9926604
    Abstract: Methods for differentiating squamous cell carcinoma from pseudoepitheliomatous hyperplasia in a biological sample using KRT9 and C15orf48, methods of using differentially expressed genes as prognostic markers for squamous cell carcinoma, methods of using molecular pathways as targets for the treatment of squamous cell carcinoma, and diagnostic kits therefor.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: March 27, 2018
    Assignee: The Regents of the University of California
    Inventors: XinMin Li, Jian Zhou, Scott W. Binder, Seong Ra
  • Patent number: 9914976
    Abstract: Provided are methods and compositions for determining an increased likelihood of prostate cancer cells in a subject to metastasize.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: March 13, 2018
    Assignee: FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FA
    Inventor: Romonia Renee Reams
  • Patent number: 9903797
    Abstract: An object of the present invention is to provide: a staining agent for tissue staining which has an improved fluorescence signal evaluation accuracy; and a tissue staining kit comprising the staining agent. The staining agent for tissue staining contains, as a staining component, dye-resin particles comprising thermosetting resin particles and a fluorescent dye immobilized on the resin particles, wherein the resin particles contains a substituent having an electric charge opposite to that of the fluorescent dye and forms an ionic bond or a covalent bond with the fluorescent dye, and the dye-resin particles have a particle size variation coefficient of 15% or less.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: February 27, 2018
    Assignee: KONICA MINOLTA, INC.
    Inventors: Kensaku Takanashi, Yasushi Nakano, Takeshi Isoda, Hideki Gouda
  • Patent number: 9903871
    Abstract: An embodiment of the invention relates to the use of stabilized cancer peptide fragments derived from “redoxin proteins” selected from the group consisting of thioredoxin; peroxiredoxin-1, 2 and 3; glutaredoxin-3; glutathione peroxidase-4; and nucleoredoxins for the diagnosis of cancers, particularly pancreatic cancer. A method for the detection of cancer, severity of cancer, and/or effectiveness of a therapeutic regimen comprises detecting and/or measuring the amount of redoxin peptide fragments present in the biological sample of a subject.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: February 27, 2018
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventors: Frank N. Chang, George P. Tuszynski
  • Patent number: 9896730
    Abstract: The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further provides methods for treating patients with cancer that incorporate these methods.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: February 20, 2018
    Assignees: OSI Pharmaceuticals, LLC, AVEO PHARMACEUTICALS, INC.
    Inventors: Julie Kan, Stuart Thomson, Gretchen M. Argast, Matthew E. O'Connor, Murray Robinson, Bin Feng, Joerg Heyer, Maria I. Chiu, Richard Nicoletti
  • Patent number: 9891224
    Abstract: The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing aggressive prostate cancer. In one embodiment, a method for identifying patients as having or likely to have aggressive prostate cancer comprises the steps of (a) obtaining a biological sample from the patient; (b) performing an assay on the biological sample to detect fucosylated fucosylated DPP-4, sTIE-2, sVEGFR-1, and FUT8; and (c) identifying the patient as having or likely to have aggressive prostate cancer if there is a statistically significant difference in the levels of fucosylated TIMP-1, fucosylated DPP-4, sTIE-2, sVEGFR-1 and FUT8.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: February 13, 2018
    Assignee: The Johns Hopkins University
    Inventors: Danni Li, Daniel W. Chan, Hui Zhang, Xiangchun Wang
  • Patent number: 9849101
    Abstract: A method for enhancing amidohydrolase activity of Fatty Acid Amide Hydrolase (FAAH) is disclosed. The method comprising administering a phenoxyacyl-ethanolamide that causes the enhanced activity. The enhanced activity can have numerous effects on biological organisms including, for example, enhancing the growth of certain seedlings.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: December 26, 2017
    Assignees: Research Foundation of the City University of New York, The Curators of the University of Missouri, University of North Texas
    Inventors: George John, Subbiah Nagarajan, Kent Chapman, Lionel Faure, Peter Koulen
  • Patent number: 9845361
    Abstract: The invention relates to recognition molecules directed towards tumors, and it also relates to pharmaceutical compositions comprising said recognition molecules, methods for the production of said recognition molecules, and to the use of said recognition molecules in the diagnosis and therapy of tumor diseases.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: December 19, 2017
    Assignee: GLYCOTOPE GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Renate Stahn, Uwe Karsten
  • Patent number: 9840557
    Abstract: The present invention provides antibodies that bind to human interleukin-25 (IL-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human IL-25 with high affinity. In certain embodiments, the invention includes antibodies that bind human IL-25 and block IL-25-mediated cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies. The antibodies of the invention are useful for the treatment of various disorders associated with IL-25 activity or expression, including asthma, allergy, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, atopic dermatitis (AD), and Eosinophilic Granulomatosis with Polyangiitis (EGPA), also know as Churg-Strauss Syndrome.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: December 12, 2017
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jamie M. Orengo, Jeanne Allinne
  • Patent number: 9825577
    Abstract: A drive control device of a motor includes a comparison unit for comparing a first voltage value, which increases or decreases depending on a current value obtained in an inverter unit of the motor, with a reference voltage value, and an arithmetic processing unit for determining presence or absence of an overcurrent based on a comparison result of the comparison unit. The arithmetic processing unit includes a first terminal and a second terminal. The comparison result of the comparison unit is inputted to the first terminal. The second terminal receives the input of the first voltage value and outputs an operation confirmation signal to the comparison unit at predetermined timings. The arithmetic processing unit determines an overcurrent state based on the first voltage value and determines a state of the first terminal based on an output timing of the operation confirmation signal from the second terminal.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: November 21, 2017
    Assignee: NIDEC SERVO CORPORATION
    Inventor: Masatomo Ishikawa
  • Patent number: 9816995
    Abstract: The present invention provides a protein-based biomarker that is useful in qualifying ovarian cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarker can be detected by SELDI mass spectrometry.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: November 14, 2017
    Assignees: Vermillion, Inc., The Johns Hopkins University
    Inventors: Zhen Zhang, Daniel W. Chan, Eric T. Fung, Zheng Wang, Fujun Zhang
  • Patent number: 9810690
    Abstract: Provided herein are compositions, reactions mixtures, mutant Ras proteins, kits, substrates, and systems for selecting a Ras antagonist, as well as methods of using the same.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: November 7, 2017
    Assignee: ARAXES PHARMA LLC
    Inventors: Matthew P. Patricelli, Ulf Peters, Liansheng Li, Pingda Ren, Yi Liu
  • Patent number: 9808504
    Abstract: The present invention provides a peptide having an amino acid sequence as set forth in SEQ ID NOs: 1 through 95 and any combination thereof. The peptide or combination of peptides possess OCT4 specific inducibility. The peptide or combination of peptides can further be used as a vaccine.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: November 7, 2017
    Assignee: Yale University
    Inventors: Kavita Dhodapkar, Madhav Dhodapkar
  • Patent number: 9797886
    Abstract: The purpose of the present invention is to provide an agglutination enhancer which shows superior agglutination enhancing effect to those of conventional immunoagglutination enhancers, and the present invention relates to an agglutination enhancer for an immunoagglutination measurement method which comprises a polymer having a monomer unit shown by the following general formula [1]: (Wherein R1 represents a hydrogen atom or a methyl group; R2 and R3 independently represent a methyl group or an ethyl group, respectively; X represents —NH— or an oxygen atom; n represents an integer of 1 to 6; and m represents an integer of 1 to 3), and an immunoagglutination measurement method in which, in the coexistence of the above-described agglutination enhancer for immunoagglutination measurement method, an antibody against analyte or an antigen for the analyte is brought into contact with the analyte to cause an antigen-antibody reaction.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: October 24, 2017
    Assignee: Wako Pure Chemical Industries, Ltd.
    Inventors: Naoyuki Yamamoto, Tsutomu Masuda
  • Patent number: 9790553
    Abstract: Cervical cancer cells and HPV+ head and neck cancer cells express three testis-specific genes not normally expressed in somatic cells: testicular cell adhesion molecule 1 (TCAM1), synaptonemal complex protein 2 (SYCP2) and stromal antigen 3 (STAG3). Among the three markers, TCAM1 and SYCP2 are early detection markers. Various methods for identifying a human or non-human animal as a candidate for further examination for cervical cancer, preneoplastic lesion for cervical cancer, head and neck cancer, or preneoplastic lesion for head and neck cancer are disclosed. Methods of detecting said cancers and preneoplastic lesions, methods of screening for drugs for treating said cancers and preneoplastic lesions, methods for monitoring the effectiveness of a treatment for said cancers, and methods of treating said cancers are also disclosed. Further disclosed are kits that can be used to practice the above methods.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: October 17, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Dohun Pyeon, Paul F. Lambert, Michael A. Newton, Paul G. Ahlquist